Malignant Pleural Effusion - Pipeline Review, H1 2018

  • ID: 4482724
  • Report
  • 35 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Advantagene Inc
  • Biogen Inc
  • Genelux Corp
  • MORE
Malignant Pleural Effusion - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Malignant Pleural Effusion - Pipeline Review, H1 2018, provides an overview of the Malignant Pleural Effusion (Respiratory) pipeline landscape.

Malignant pleural effusion is a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue (pleura) lining the outside of the lung and the wall of the chest cavity. Lung cancer, breast cancer, lymphoma, and leukemia cause most malignant pleural effusions.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Malignant Pleural Effusion - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Malignant Pleural Effusion (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Pleural Effusion (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Malignant Pleural Effusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 4 and 1 respectively.

Malignant Pleural Effusion (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Pleural Effusion (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Malignant Pleural Effusion (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malignant Pleural Effusion (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malignant Pleural Effusion (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Pleural Effusion (Respiratory)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malignant Pleural Effusion (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malignant Pleural Effusion (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Advantagene Inc
  • Biogen Inc
  • Genelux Corp
  • MORE
Introduction

Report Coverage

Malignant Pleural Effusion - Overview

Malignant Pleural Effusion - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Malignant Pleural Effusion - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Malignant Pleural Effusion - Companies Involved in Therapeutics Development

Advantagene Inc

Biogen Inc

Genelux Corp

Malignant Pleural Effusion - Drug Profiles

BG-00001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Malignant Pleural Effusion - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Malignant Pleural Effusion and Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLONC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methotrexate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PTS-500 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Malignant Pleural Effusion - Dormant Projects

Malignant Pleural Effusion - Product Development Milestones

Featured News & Press Releases

May 12, 2015: Genelux to Present Posters Supporting Lead Oncolytic Viral Therapy GL-ONC1 at ASCO Annual Meeting

Jun 15, 2013: Genelux Presents Abstracts at the 7th International Meeting on Replicating Oncolytic Virus Therapeutics in Quebec

May 30, 2013: Genelux To Present Abstracts For Clinical Trials Of Oncolytic Viral Therapy GL-ONC1 At 2013 ASCO Annual Meeting

Feb 06, 2013: Genelux Announces Treatment Of First Patient In Phase I Trial With GL-ONC1 At Memorial Sloan Kettering Cancer Center

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Malignant Pleural Effusion, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Malignant Pleural Effusion - Pipeline by Advantagene Inc, H1 2018

Malignant Pleural Effusion - Pipeline by Biogen Inc, H1 2018

Malignant Pleural Effusion - Pipeline by Genelux Corp, H1 2018

Malignant Pleural Effusion - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Malignant Pleural Effusion, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Advantagene Inc
  • Biogen Inc
  • Genelux Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll